compromised by increases in blood pressure. Cases of elevated blood
pressure requiring immediate treatment have been reported.
-- SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding
events. Concomitant use of aspirin, NSAIDs, warfarin, and other
anticoagulants may add to this risk.
-- Mydriasis has been reported in association with PRISTIQ; therefore,
patients with raised intraocular pressure or those at risk of acute
narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
-- As with all antidepressants, PRISTIQ should be used cautiously in
patients with a history or family history of mania or hypomania.
-- Caution is advised in administering PRISTIQ to patients with
cardiovascular, cerebrovascular, or lipid metabolism disorders.
Increases in blood pressure and small increases in heart rate were
observed in clinical studies with PRISTIQ.
-- Dose-related elevations in fasting serum total cholesterol, LDL (low
density lipoprotein) cholesterol, and triglycerides were observed in
clinical studies. Measurement of serum lipids should be considered
during PRISTIQ treatment.
-- Symptoms associated with discontinuation of PRISTIQ have been reported.
Patients should be monitored for symptoms when discontinuing treatment.
A gradual reduction in dose rather than abrupt cessation is recommended
-- Dosage adjustment (50 mg every other day) is necessary in patients with
severe renal impairment or end-stage renal disease (ESRD). The dose
should not be escalated in patients with moderate or severe renal
impairment or ESRD.
-- Products containing desvenlafaxine and products containing venlafaxine
should not be used concomitantly with PRIST
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved